Transcriptomic screening of novel targets of sericin in human hepatocellular carcinoma cells
Issued Date
2024-12-01
Resource Type
eISSN
20452322
Scopus ID
2-s2.0-85186593080
Journal Title
Scientific Reports
Volume
14
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Scientific Reports Vol.14 No.1 (2024)
Suggested Citation
Jantaravinid J., Tirawanchai N., Ampawong S., Kengkoom K., Somkasetrin A., Nakhonsri V., Aramwit P. Transcriptomic screening of novel targets of sericin in human hepatocellular carcinoma cells. Scientific Reports Vol.14 No.1 (2024). doi:10.1038/s41598-024-56179-y Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/97572
Title
Transcriptomic screening of novel targets of sericin in human hepatocellular carcinoma cells
Corresponding Author(s)
Other Contributor(s)
Abstract
Sericin, a natural protein derived from Bombyx mori, is known to ameliorate liver tissue damage; however, its molecular mechanism remains unclear. Herein, we aimed to identify the possible novel targets of sericin in hepatocytes and related cellular pathways. RNA sequencing analysis indicated that a low dose of sericin resulted in 18 differentially expressed genes (DEGs) being upregulated and 68 DEGs being downregulated, while 61 DEGs were upregulated and 265 DEGs were downregulated in response to a high dose of sericin (FDR ≤ 0.05, fold change > 1.50). Functional analysis revealed that a low dose of sericin regulated pathways associated with the complement and coagulation cascade, metallothionine, and histone demethylate (HDMs), whereas a high dose of sericin was associated with pathways involved in lipid metabolism, mitogen-activated protein kinase (MAPK) signaling and autophagy. The gene network analysis highlighted twelve genes, A2M, SERPINA5, MT2A, MT1G, MT1E, ARID5B, POU2F1, APOB, TRAF6, HSPA8, FGFR1, and OGT, as novel targets of sericin. Network analysis of transcription factor activity revealed that sericin affects NFE2L2, TFAP2C, STAT1, GATA3, CREB1 and CEBPA. Additionally, the protective effects of sericin depended on the counterregulation of APOB, POU2F1, OGT, TRAF6, and HSPA5. These findings suggest that sericin exerts hepatoprotective effects through diverse pathways at different doses, providing novel potential targets for the treatment of liver diseases.